This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
United Therapeutics Stock Surges 32% in 6 Months: Here's Why
by Zacks Equity Research
UTHR shares jump 32% in six months as Tyvaso sales surge, earnings grow and Phase III TETON-2 data open a potential new market in IPF.
UTHRNegative Net Change ANIPNegative Net Change CSTLNegative Net Change
biotechs
AXSM's 2025 Revenue Surge Largely Driven by Auvelity: What's Ahead?
by Kanishka Das
Axsome's lead product, Auvelity, sales jumped 74% to $507M in 2025, fueling growth while other drugs added momentum.
JAZZNegative Net Change ACADPositive Net Change AXSMNegative Net Change
biotechs
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
ALLO posts a narrower Q4 loss than expected, cuts expenses and advances key CAR-T studies, with cash projected to fund operations into 2028.
ANIPNegative Net Change ALLONegative Net Change ALXOPositive Net Change
biotechs earnings medical
Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise?
by Zacks Equity Research
Gilead plans a $7.8B Arcellx acquisition as cell therapy sales decline, seeking full control of anito-cel to strengthen its oncology pipeline.
NVSNegative Net Change BMYPositive Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
ImmunityBio Stock Soars 295% YTD: Time to Buy, Hold or Sell?
by Sundeep Ganoria
IBRX stock surges nearly 300% YTD as Anktiva sales jump and global approvals expand, while premium valuation and single-drug reliance raise questions.
RHHBYPositive Net Change BMYPositive Net Change MRKPositive Net Change IBRXNegative Net Change
biotechnology biotechs cancer cell-therapy medical pharmaceuticals
RARE's DTX301 Meets First Key Goal in Phase III OTC Deficiency Study
by Zacks Equity Research
Ultragenyx Pharmaceutical reports phase III success for DTX301 in OTC deficiency, lowering ammonia 18% compared to placebo and keeping levels normal through 36 weeks.
USNAPositive Net Change RARENegative Net Change ALXOPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
RLMD Stock Surges 42% in a Week: Here's What You Should Know
by Zacks Equity Research
Relmada Therapeutics jumps 42% in a week after reporting encouraging efficacy and safety data from a mid-stage bladder cancer study of NDV-01, simultaneously sharing phase III plans.
USNAPositive Net Change RLMDNegative Net Change ALXOPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Will Policy Shifts Accelerate Demand for Eli Lilly's GLP-1 Drugs?
by Ahan Chakraborty
LLY is likely to see stronger demand for its GLP-1 drugs as Medicare expands coverage and the company prepares to launch an oral obesity treatment.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy?
by Kanishka Das
Ironwood and Puma Biotechnology are developing GI and cancer therapies, respectively, with sales of their sole drugs expected to support 2026 revenues.
IRWDNegative Net Change ABBVPositive Net Change PBYINegative Net Change
biotechs medical
Is Bristol Myers' Deep Pipeline the Key to Future Growth?
by Ekta Bagri
BMY highlights a deep pipeline with multiple late-stage candidates and registrational data expected in 2026, reinforcing confidence in its next-gen CELMoD program.
BMYPositive Net Change JNJPositive Net Change PFENegative Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals